Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) on Tuesday, plunged -5.28% from the previous trading day, before settling in for the closing price of $270.02. Within the past 52 weeks, ALNY’s price has moved between $141.98 and $304.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 63.53% annually for the last half of the decade. The company achieved an average annual earnings per share of 18.25%. With a float of $124.35 million, this company’s outstanding shares have now reached $129.29 million.
In an organization with 2230 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.62%, operating margin of -7.87%, and the pretax margin is -16.79%.
Alnylam Pharmaceuticals Inc (ALNY) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Alnylam Pharmaceuticals Inc is 4.40%, while institutional ownership is 95.03%. The most recent insider transaction that took place on Mar 24 ’25, was worth 1,633,500. In this transaction CMO & EVP Dev & Med Affairs of this company sold 5,445 shares at a rate of $300.00, taking the stock ownership to the 20,221 shares. Before that another transaction happened on Mar 21 ’25, when Company’s CMO & EVP Dev & Med Affairs sold 4,321 for $285.00, making the entire transaction worth $1,231,485. This insider now owns 20,221 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.25% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Alnylam Pharmaceuticals Inc (ALNY) is currently performing well based on its current performance indicators. A quick ratio of 2.71 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach 1.43 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was better than the volume of 0.79 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 32.25%. Additionally, its Average True Range was 12.43.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 36.46%, which indicates a significant increase from 27.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.15% in the past 14 days, which was higher than the 44.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $260.30, while its 200-day Moving Average is $256.61. However, in the short run, Alnylam Pharmaceuticals Inc’s stock first resistance to watch stands at $267.87. Second resistance stands at $279.97. The third major resistance level sits at $286.34. If the price goes on to break the first support level at $249.39, it is likely to go to the next support level at $243.02. Assuming the price breaks the second support level, the third support level stands at $230.92.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
Market capitalization of the company is 33.27 billion based on 130,085K outstanding shares. Right now, sales total 2,248 M and income totals -278,160 K. The company made 593,170 K in profit during its latest quarter, and -83,760 K in sales during its previous quarter.
